Genmab — Februar 2021
-
God morgen.
-
Asien: Generel fremgang men Tokyo halter efter: https://www.proinvestor.com/investornyt/671940/asien-generel-fremgang-men-tokyo-halter-efter
-
Onsdagens aviser med Demant, Danske Bank og TDC: https://www.proinvestor.com/investornyt/671939/onsdagens-aviser-med-demant-danske-bank-og-tdc
-
Aktier/tendens: Vild regnskabsdag med A.P. Møller-Mærsk og mange andrehttps://www.proinvestor.com/investornyt/671958/aktier-tendens-vild-regnskabsdag-med-ap-moller-maersk-og-mange-andre
-
if anyone has access to scrip.pharmaintelligence.informa ; you can tell us if there is anything useful in this article
https://scrip.pharmaintelligence.informa.com/SC143792/Genmab-Commercial-Expansion-Opens-The-Door-To-New-Types-Of-Deals -
Looks interesting...
-
Several drugs developed by Genmab A/S are already on the market, but the company is planning to participate in its first commercial launch in 2021. Genmab is preparing for the US launch of the antibody-drug conjugate tisotumab vedotin for metastatic cervical cancer in the second half of the year in partnership with Seagen Inc. , if it is approved by the US Food and Drug Administration as expected.
The companies plan to file tisotumab vedotin for accelerated approval for metastatic cervical canc
-
cancer based on positive Phase II data. (Also see "Genmab And Seattle Genetics Progress Cervical Cancer ADC" - Scrip, 30 Jun, 2020.)
It is a transitional year for Genmab as it begins to build out a commercial footprint for the first time. The Danish biotech has developed several drugs that have reached the market, but those drugs have been launched by the company's partners. They include Johnson & Johnson's Darzalex (daratumumab), Novartis AGs' Kesimpta (ofatumumab) and Horizon Therapeutics plc
-
Tepezza (teprotumumab) – and Genmab receives sales royalties on all of them.
"This is probably one of our most exciting years ever for the company," CEO Jan van de Winkel said in a recent interview. "To become an end-to-end integrated biotech, a powerhouse, directly delivering new molecules to patients with the Genmab name on the vial is a big thrill for us."
The company is taking a cautious, stepwise approach to building out a commercial organization, focusing on the US and Japan. The team wi
-
50/50 Deals At Least
The company's commercial evolution will impact its partnering strategy going forward as Genmab looks to hold onto more commercial rights for its products and eventually launch drugs independently. For example, a rich $750m upfront deal the company signed last year with AbbVie Inc. to develop and commercialize three next-generation bispecific antibody candidates included co-commercialization rights in the US and Japan and an option to co-promote in other regions for two of th -
the products. (Also see "Genmab Lands Experienced Partner AbbVie In Broad Bispecific Antibody Collaboration" - Scrip, 10 Jun, 2020.)
"At a minimum, we will ask for 50% co-ownership," van de Winkel said, pointing to the AbbVie partnership as an example of the kinds of deals Genmab hopes to mirror in the future. "That is one of the nice things about the AbbVie relationship, they were perfectly on board to do 50/50 with us.
-
Wealthier biotechs are gaining new leverage when it comes to deal-making, van de Winkel added. "The dynamics between smaller biotech companies and bigger players is changing right now because some of the biotech companies, like Genmab, are very well capitalized."
Genmab also plans to retain full ownership of some molecules, at least in the regions where it builds up a commercial presence.
-
"It's difficult to say right now which molecule it will be [that] we will hang onto 100%," he said. If it is a drug targeted to a smaller cancer indication that can be marketed optimally with a specialized sales force, then that would be an appropriate candidate to launch independently, but for a drug with broad reach like Darzalex, the exec explained Genmab will still look to partner, particularly because of the broad scope of the clinical development program.
-
The most advanced candidate in the deal with AbbVie is epcoritamab (CD3xCD20), which moved into Phase III testing in diffuse large B-cell lymphoma (DLBCL) early this year. (Also see "Genmab/AbbVie’s Epcoritamab Advances As Deal Bears Fruit" - Scrip, 14 Jan, 2021.) The deal also includes two other bispecific antibody candidates developed using Genmab's DuoHexaBody and DuoBody development platforms, which Genmab expects will continue to deliver drug candidates into the pipeline.
-
Bispecific antibodies are getting a lot of attention, although toxicity concerns remain. Genmab is developing a PD-L1x4-1BB bispecific antibody in early clinical testing in solid tumors in collaboration with BioNTech SE a collaboration dating back to 2015 that gives Genmab 50/50 commercial rights.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind